This more active form of 3β-HSD1 is inherited in about half of all patients with CRPC and drives more aggressive clinical outcomes and shorter overall survival after treatment with ADT, thus providing genetic evidence for HSD3B1 in promoting resistance in clinical prostate cancer (7, 29, 30). Here, HSD3B1 is linked to prostate cancer.